Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Fishbane

Showing results (101-110 of 234) with videos related to

Pageof 24
Sort By:
Clinical Kidney Journal|February 26, 2015
Challenges and opportunities in late-stage chronic kidney diseaseSteven Fishbane, Azzour D Hazzan, Candice Halinski, et al.
American Journal of Nephrology|January 25, 2017
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease PatientsFrancesco Locatelli, Steven Fishbane, Geoffrey A Block, et al.
The New England Journal of Medicine|November 9, 2019
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with PruritusSteven Fishbane, Aamir Jamal, Catherine Munera, et al.
Kidney International|October 31, 2020
The authors replyJia H Ng, Jamie S Hirsch, Kenar D Jhaveri, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2020
Phospholipase A<sub>2</sub> Receptor Antibody-Positive Pregnancy: A Case ReportMala Sachdeva, Laurence H Beck, Ilene Miller, et al.
Kidney International|March 14, 2008
Managing anemia in dialysis patients: hemoglobin cycling and overshootAjay K Singh, Edgar Milford, Steven Fishbane, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 10, 2009
More on renal salt wasting without cerebral disease: response to saline infusionSolomon Bitew, Louis Imbriano, Nobuyuki Miyawaki, et al.
Nephrology News & Issues|December 21, 2012
Interpreting changes to the ESRD quality incentive programSteven Fishbane, Ilene Miller, Naveed N Masani, et al.
Kidney International Reports|September 14, 2019
Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney DiseaseSteven Fishbane, Bruce S Spinowitz, Wayne A Wisemandle, et al.
Kidney International|August 14, 2016
Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting SystemKenar D Jhaveri, Vipulbhai Sakhiya, Rimda Wanchoo, et al.
Pageof 24

Showing results (101-110 of 234) with videos related to

Sort By:
Pageof 24
Clinical Kidney Journal|February 26, 2015
Challenges and opportunities in late-stage chronic kidney diseaseSteven Fishbane, Azzour D Hazzan, Candice Halinski, et al.
American Journal of Nephrology|January 25, 2017
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease PatientsFrancesco Locatelli, Steven Fishbane, Geoffrey A Block, et al.
The New England Journal of Medicine|November 9, 2019
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with PruritusSteven Fishbane, Aamir Jamal, Catherine Munera, et al.
Kidney International|October 31, 2020
The authors replyJia H Ng, Jamie S Hirsch, Kenar D Jhaveri, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2020
Phospholipase A<sub>2</sub> Receptor Antibody-Positive Pregnancy: A Case ReportMala Sachdeva, Laurence H Beck, Ilene Miller, et al.
Kidney International|March 14, 2008
Managing anemia in dialysis patients: hemoglobin cycling and overshootAjay K Singh, Edgar Milford, Steven Fishbane, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 10, 2009
More on renal salt wasting without cerebral disease: response to saline infusionSolomon Bitew, Louis Imbriano, Nobuyuki Miyawaki, et al.
Nephrology News & Issues|December 21, 2012
Interpreting changes to the ESRD quality incentive programSteven Fishbane, Ilene Miller, Naveed N Masani, et al.
Kidney International Reports|September 14, 2019
Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney DiseaseSteven Fishbane, Bruce S Spinowitz, Wayne A Wisemandle, et al.
Kidney International|August 14, 2016
Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting SystemKenar D Jhaveri, Vipulbhai Sakhiya, Rimda Wanchoo, et al.
Pageof 24